Table of contents
Nephrogenic systemic fibrosis
Guidelines
Key sources
The following summarized guidelines for the evaluation and management of nephrogenic systemic fibrosis are prepared by our editorial team based on guidelines from the European Academy of Dermatology and Venereology (EADV 2017).
1
Screening and diagnosis
Medical management
Preventative measures
Avoidance of gadolinium-containing contrast agents
As per EADV 2017 guidelines:
Avoid using high-risk gadolinium-based contrast agents, especially in patients with an eGFR of < 30 mL/min, for the prevention of nephrogenic systemic fibrosis.
D
Use a low-risk gadolinium medium and reduce the dose of the gadolinium-based contrast agents to the minimum effective dosage for imaging if MRI with gadolinium-based contrast agents is indispensable.
E
More topics in this section
Dialysis